Brief: BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
08/12/2020 12:15
Dec 8 (Reuters) - BELLUS Health Inc BLU.TO :
* BELLUS HEALTH ANNOUNCES FIRST PATIENT DOSED IN ITS PHASE
2B
SOOTHE TRIAL OF BLU-5937 FOR THE TREATMENT OF REFRACTORY CHRONIC
COUGH
Source text for Eikon: ID:nBw7g8mV2a
Further company coverage: BLU.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BELLUS Health
See all newsBrief: Bellus Health Inc. Calls Special Shareholders’ Meeting In Connection With Gsk Acquisition
Brief: Bellus Health Reports First Quarter 2023 Financial Results And Business Highlights
Press Digest: British Business - April 19
Canada Stocks: Toronto market extends winning streak on 'soft landing' hopes
Bellus soars as GSK plans to buy drug developer for $2 bln